Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) - Total Assets
Based on the latest financial reports, Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) holds total assets worth CN¥10.31 Billion CNY (≈ $1.51 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Nanjing King-friend Biochemical Pharmace book value and equity for net asset value and shareholders' equity analysis.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Nanjing King-friend Biochemical Pharmaceutical Co Ltd's total assets of CN¥10.31 Billion consist of 74.1% current assets and 25.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.8% |
| Accounts Receivable | CN¥1.19 Billion | 12.6% |
| Inventory | CN¥3.67 Billion | 38.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥796.08 Million | 8.4% |
| Goodwill | CN¥129.51 Million | 1.4% |
Asset Composition Trend (2013–2024)
This chart illustrates how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Nanjing King-friend Biochemical Pharmace stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanjing King-friend Biochemical Pharmaceutical Co Ltd's current assets represent 74.1% of total assets in 2024, an increase from 73.8% in 2013.
- Cash Position: Cash and equivalents constituted 10.8% of total assets in 2024, down from 26.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 1.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 38.6% of total assets.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Nanjing King-friend Biochemical Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
|
China | CN¥4.69 Billion |
|
KPC Pharmaceuticals Inc
SHG:600422
|
China | CN¥12.01 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Cheng Du Sheng Nuo Biotec Co. Ltd. A
SHG:688117
|
China | CN¥1.91 Billion |
|
Jiangsu Jibeier Pharmaceutical Co Ltd
SHG:688566
|
China | CN¥2.64 Billion |
Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.46 | 3.13 | 2.41 |
| Quick Ratio | 1.35 | 1.51 | 0.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.47 Billion | CN¥4.73 Billion | CN¥3.96 Billion |
Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Nanjing King-friend Biochemical Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.31 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -0.2% |
| Total Assets | CN¥9.51 Billion |
| Market Capitalization | $2.15 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Nanjing King-friend Biochemical Pharmaceutical Co Ltd's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Nanjing King-friend Biochemical Pharmaceutical Co Ltd's assets decreased by 0.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Nanjing King-friend Biochemical Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total assets of Nanjing King-friend Biochemical Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥9.51 Billion ≈ $1.39 Billion |
-0.15% |
| 2023-12-31 | CN¥9.52 Billion ≈ $1.39 Billion |
-4.85% |
| 2022-12-31 | CN¥10.01 Billion ≈ $1.46 Billion |
+21.82% |
| 2021-12-31 | CN¥8.22 Billion ≈ $1.20 Billion |
+6.43% |
| 2020-12-31 | CN¥7.72 Billion ≈ $1.13 Billion |
+52.02% |
| 2019-12-31 | CN¥5.08 Billion ≈ $743.13 Million |
+49.26% |
| 2018-12-31 | CN¥3.40 Billion ≈ $497.87 Million |
+26.26% |
| 2017-12-31 | CN¥2.69 Billion ≈ $394.33 Million |
+76.97% |
| 2016-12-31 | CN¥1.52 Billion ≈ $222.82 Million |
+17.37% |
| 2015-12-31 | CN¥1.30 Billion ≈ $189.85 Million |
-15.76% |
| 2014-12-31 | CN¥1.54 Billion ≈ $225.37 Million |
+33.08% |
| 2013-12-31 | CN¥1.16 Billion ≈ $169.34 Million |
-- |
About Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochlo… Read more